Studies of NSCLC patients receiving anti-PD-1/PD-L1 drugs have found that significant decreases in ctDNA levels are linked to immunotherapy clinical response and prolonged survival [102, 103]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.